Leap Therapeutics, Inc. - Common Stock (LPTX)

Health In Tech Inc. (NASDAQ: HIT), OSR Holdings Inc. (NASDAQ: OSRH), Theratechnologies Inc. (NASDAQ: THTX), and Leap Therapeutics Inc. (NASDAQ: LPTX) continue to push boundaries in healthcare through breakthroughs in insurtech, virtual access, immunotherapy, biologics, and precision oncology.

NEW YORK, NY / ACCESSWIRE / October 24, 2023 / The biotech sector, known for its exponential growth potential, is currently facing highly challenging market conditions. Influences like rising inflation, geopolitical tensions, and looming economic recessions have led to a sharp decline in the sector. Consequently, many small and micro-cap biotech companies are trading at all-time lows, with several down by over 80-90% in recent years. This downturn has led to many biotech firms trading below their cash holdings.

Mergers and acquisitions are common, especially across the health sector. Here are some lesser-known buyouts and how they could fare down the road.

Halper Sadeh LLC, an investor rights law firm, is investigating whether the merger of Leap Therapeutics, Inc. (NASDAQ: LPTX) and Flame Biosciences, Inc. is fair to Leap shareholders. Under the terms of the merger agreement, Leap will issue approximately 19,794,373 shares of its common stock and approximately 136,833 shares of a newly designated Series X non-voting convertible preferred stock to Flame stockholders.

Palm Beach, FL – January 20, 2022 – FinancialNewsMedia.com News Commentary – Despite significant progress in the treatment of gastric cancer, it is still among the leading causes of deaths due to cancer, across the world. The high mortality rates are primarily caused by the late diagnosis of the disease, with patients often missing the opportunity […]

Palm Beach, FL – September 17, 2021 – FinancialNewsMedia.com News Commentary – The ovarian cancer drugs market consists of sales of ovarian cancer drugs to treat ovarian cancer. Ovarian cancer is caused due to abnormal growth of cells in ovary. This industry includes establishments that produce drugs used in chemotherapy, radiation, and surgery for treating ovarian cancer.  The rising incidence of ovarian cancer is driving the ovarian cancer drugs market. Furthermore, ovarian cancer is recorded to be the eighth most commonly occurring cancer in women and the 18th most commonly occurring cancer across the globe. According to a study by The World Ovarian Cancer Coalition an estimated 55% rise is expected in the number of patients suffering from ovarian cancer by 2035. According to the Cancer Statistics in 2020, published by the American Cancer Society’, about 1,806,590 new cancer cases and 606,520 deaths were expected in USA. Thus, the increasing incidence of ovarian cancer cases across the globe drives the ovarian cancer drugs market growth.  A report from MarketsAndMarkets said that the global ovarian cancer drugs market is expected to grow from $1.49 billion in 2020 to $1.73 billion in 2021 at a compound annual growth rate (CAGR) of 16.1%. It also said that the market is expected to reach $3.51 billion in 2025 at a CAGR of 19.3%.  Active biotech companies in the market this week include BioVaxys Technology Corp. (OTCQB: BVAXF) (CSE: BIOV), Leap Therapeutics, Inc. (NASDAQ: LPTX), Phio Pharmaceuticals Corp. (NASDAQ: PHIO), aTyr Pharma, Inc. (NASDAQ: LIFE), Eloxx Pharmaceuticals, Inc. (NASDAQ: ELOX).